קארדוכסין פורטה - Cardoxin forte
ש××× ×× !
×ת×ר××: 25.10.2017 ×תק××× ××××¢× ×× ×©××××§ ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 25.10.2017 ×תק××× ××××¢× ×× ×©××××§ ×תר××¤× ××פסק ×צ××ת×ת.
××§×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש××××§ תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||
|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | B01AC Platelet aggregation inhibitors excluding heparin | |||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | פ××× - PER OS | |||||
| צ×רת ××× ×× | ×××××, TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | As an adjunct to oral anticoagulants for prophylaxis of thromboembolism associated with prosthetic heart valves. Reduction of proteinuria in the nephrotis syndrome. Treatment of membranoproliferative glomerulonephritis. Prevention of pre-eclampsia in the final trimester of pregnancy. Prevention of transplant artery stenosis. Prevention of post-operative thromboembolic complications of coronary artery surgery. In combination with acetylsalicylic acid in cases of recurrent deep vein thrombosis resistant to oral anticoagulants. Prevention of thrombogenic manifestations. As an alternative to exercise stress in thallium myocardial imaging particularly in patients unable to exercise or in those for whom exercise may be contraindicated.
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 Â
| |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ×§×ר×××ס×× ×¤×ר×× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | RAFA LABORATORIES LTD, JERUSALEM |
| ×©× ××¢× ×ר×ש×× | RAFA LABORATORIES LTD |
| ר×ש××× | ת×ר×× ××ש×: 08/1970. ר×ש××× ×ת×ר××: 06/2012 |
| ת×ר×× ×¢×××× ××ר×× | 25.10.2017 |